$-1.60 EPS Expected for Esperion Therapeutics, Inc. (ESPR)

October 13, 2018 - By whatsonthorold

Investors sentiment decreased to 0.95 in 2018 Q2. Its down 0.55, from 1.5 in 2018Q1. It turned negative, as 43 investors sold Esperion Therapeutics, Inc. shares while 35 reduced holdings. 18 funds opened positions while 56 raised stakes. 26.84 million shares or 9.29% more from 24.56 million shares in 2018Q1 were reported.
Weiss Asset Mgmt L P stated it has 5,427 shares. Tiaa Cref Inv Management Limited Liability Com, New York-based fund reported 50,241 shares. Pictet Asset Management Limited owns 345,671 shares or 0.03% of their US portfolio. Bamco Ny invested in 15,900 shares. Sg Americas Secs Ltd Liability holds 0.01% or 27,319 shares. J Goldman L P holds 0.19% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 92,691 shares. Pub Employees Retirement Of Ohio holds 0% or 24,064 shares. Edge Wealth Ltd Liability Corp reported 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Macquarie Group Ltd invested 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Btg Pactual Global Asset Management owns 0.1% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 8,719 shares. Parkside Fincl Retail Bank holds 0.01% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 500 shares. The New York-based Citigroup has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). 8,500 were accumulated by Canada Pension Plan Inv Board. Victory Cap Management has 0% invested in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Parametric Assocs Limited Company holds 0% or 21,079 shares in its portfolio.

Analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report $-1.60 EPS on November, 6.They anticipate $0.26 EPS change or 13.98 % from last quarter’s $-1.86 EPS. After having $-1.71 EPS previously, Esperion Therapeutics, Inc.’s analysts see -6.43 % EPS growth. The stock increased 0.22% or $0.1 during the last trading session, reaching $46.22. About 356,303 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has declined 8.71% since October 14, 2017 and is downtrending. It has underperformed by 24.33% the S&P500.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 8 analysts covering Esperion (NASDAQ:ESPR), 4 have Buy rating, 3 Sell and 1 Hold. Therefore 50% are positive. Esperion had 9 analyst reports since April 19, 2018 according to SRatingsIntel. The rating was downgraded by Northland Capital to “Market Perform” on Wednesday, July 11. The firm has “Buy” rating given on Wednesday, May 2 by JMP Securities. The stock has “Buy” rating by Citigroup on Friday, August 17. As per Thursday, May 3, the company rating was downgraded by JP Morgan. The firm has “Outperform” rating given on Friday, May 4 by Credit Suisse. The rating was maintained by Deutsche Bank on Thursday, May 3 with “Buy”. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Buy” rating by Northland Capital on Thursday, April 19. Bank of America downgraded the shares of ESPR in report on Wednesday, May 2 to “Underperform” rating. The company was downgraded on Thursday, May 3 by J.P. Morgan.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.24 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Another recent and important Esperion Therapeutics, Inc. (NASDAQ:ESPR) news was published by Seekingalpha.com which published an article titled: “Esperion Therapeutics: Hold For PDUFA Date” on September 25, 2018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>